<DOC>
	<DOCNO>NCT00204607</DOCNO>
	<brief_summary>vaccination protocol induce specific immune response melanoma associate antigen intradermal injection mRNA cod correspond antigen</brief_summary>
	<brief_title>Intradermal Vaccination With Stabilized Tumor mRNA - Clinical Phase I/II Trial Melanoma Patients</brief_title>
	<detailed_description>vaccination protocol induce specific immune response melanoma associate antigen intradermal injection mRNA cod correspond antigen . Antigens use Melan-A , Mage-A1 , Mage-A3 , Survivin , GP100 Tyrosinase . GM-CSF use adjuvans . Phase I/II clinical trial analyse safety immune respones stage III/IV melanoma patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>stage III/IV fresh frozen tumortissue age 1875 informed consent give Karnofsky &gt; = 70 % systemic glucocorticoid brain metestasis malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>